GlassScriptPhysician profile
Trisha Bhat Scharff
NPI 1669040853
$3,800.85
in general payments reported to CMS, 2019-2025
13 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $226 · 2023: $2,466 · 2024: $303 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,974 · Food and Beverage: $1,502 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,973.71 |
| Food and Beverage | $1,501.78 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,668.32 | 2022-2025 | Natrelle Saline-Filled Breast Implants, Revolve, Rinvoq |
| Janssen Biotech, INC. | $269.48 | 2024-2025 | Tremfya |
| Ucb, INC. | $156.60 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $138.62 | 2025 | Sotyktu |
| Dermavant Sciences, INC. | $138.28 | 2024 | Vtama |
| Janssen Scientific Affairs, LLC | $124.24 | 2025 | Tremfya |
| Lilly USA, LLC | $122.78 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $48.28 | 2023-2024 | Libtayo |
| Organon LLC | $34.66 | 2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $30.88 | 2025 | |
| Revance Therapeutics, INC. | $30.23 | 2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $20.91 | 2025 | |
| Botanix Sb INC | $17.57 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Scharff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.